FIG. 7.

Changes in cardiac morphology and function in doxorubicin-treated mice. (A–C) Changes in cardiac morphology and (D–F) function in vehicle- (n = 5), doxorubicin- (n = 7), and doxorubicin and pargyline-treated mice (n = 5). *p < 0.05, ^#p < 0.01, ^çp < 0.001 versus Vehicle; ^§p < 0.01, ^$p < 0.001 versus Doxo by one-way ANOVA with post hoc Tukey's multiple comparison test. Where data were not normally distributed, the Kruskal–Wallis test has been applied. Data are expressed as mean ± SEM. EF, ejection fraction; FS, fractional shortening; LV mass/BW, left ventricle mass/body weight; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension.